Sean Moloughney06.05.09
Under terms of a new agreement, Bayer Healthcare, LLC, Morristown, NJ, will commercialize the proprietary products of Neptune Technologies & Bioressources, Laval, Quebec, Canada, in the U.S.
The alliance with Bayer represents one milestone in Neptune’s strategic development plan to penetrate global nutraceutical and pharmaceutical markets in collaboration with international partners.
“It has been strategic to invest the time and resources into building a complete portfolio of scientific data, intellectual property and regulatory approvals, which ultimately allowed the company to attract the best partner," said Dr. Tina Sampalis, chief scientific officer.
"Neptune's approach to commercialization consists of rapidly penetrating the market to generate short-term revenue and growth by partnering with the right marketer that can create broad consumer awareness leveraged by our substantial scientific data and that can create large market share for Neptune," she added.
The alliance with Bayer represents one milestone in Neptune’s strategic development plan to penetrate global nutraceutical and pharmaceutical markets in collaboration with international partners.
“It has been strategic to invest the time and resources into building a complete portfolio of scientific data, intellectual property and regulatory approvals, which ultimately allowed the company to attract the best partner," said Dr. Tina Sampalis, chief scientific officer.
"Neptune's approach to commercialization consists of rapidly penetrating the market to generate short-term revenue and growth by partnering with the right marketer that can create broad consumer awareness leveraged by our substantial scientific data and that can create large market share for Neptune," she added.